China
Africa
Explore chapters and articles related to this topic
The Role of Nanotechnology in the Treatment of Drug Resistance Cancer
Published in Bhaskar Mazumder, Subhabrata Ray, Paulami Pal, Yashwant Pathak, Nanotechnology, 2019
Sandipan Dasgupta, Anup Kumar Das, Paulami Pal, Subhabrata Ray, Bhaskar Mazumder
Unfortunately, drugs such as antimetabolites, alkylating agents, and platinum compounds, which were successfully used in the treatment of malignancies, are suffering from MDR and are not easily substituted with non-MDR drugs. Drugs like anthracyclines and taxanes are presently unique in a range of chemotherapy regimens because of their exclusive anti-neoplastic activity. Thus, the affinity of these drugs for P-gp can be reduced by the chemical modification of their structures. In anthracyclines, the 9-alkyl substitution of the anthracene A ring and certain sugar modifications have been associated with a reduced affinity for P-gp and the maintenance of cytotoxic activity in certain MDR tumor cell lines (Coley et al., 1990; Scott et al., 1986).
Herbs in Cancer Therapy
Published in Anil K. Sharma, Raj K. Keservani, Surya Prakash Gautam, Herbal Product Development, 2020
Annum Malik, Shahzadi Sidra Saleem, Kifayat Ullah Shah, Learn-Han Lee, Bey Hing Goh, Tahir Mehmood Khan
Taxanes are one of the most effective up-to-date antitumour agents. They are used for the treatment of several cancers including lung cancer, ovarian cancer, breast cancer, Kaposi’s sarcoma, and several other metastatic cancers. Taxol or paclitaxel and taxotere or docetaxel are derived from a specie called T. brevifolia (Ireson et al. 2002). Taxanes act by inhibiting depolymerization of microtubules, that is, they target mitosis during metaphase and anaphase, thereby causing the apoptotic cellular death of the cancer cell lines. With reference to their mechanism of action, taxanes are often refered to as “spindle poisons” (Hagiwara and Sunada 2004).
Developing Taxanes for Oral Intake Employing Apt Nanocarriers
Published in Bhupinder Singh, Om Prakash Katare, Eliana B. Souto, NanoAgroceuticals & NanoPhytoChemicals, 2018
Rajneet Kaur Khurana, Teenu Sharma, Harpreet Kaur, Anchal, Kaisar Raza, Bhupinder Singh
Taxanes are being commonly prescribed for the management of diversity of cancers including non-small cell lung, ovarian, head, gastric, neck, and prostate cancers. Taxanes hold the second biggest global market of approximately 700 million USD, next only to cardiovascular agents (Jibodh et al., 2013; Kumar et al., 2016). Taxane resistance has also been observed in cancer patients, thus calling for the need for development of oral nanostructured drug-delivery systems (Hennenfent and Govindan, 2006). Table 9.3 highlights the various nanostructured delivery systems of taxanes, primarily of paclitaxel and docetaxel, reported in the literature.
Novel spray-dried PHA microparticles for antitumor drug release
Published in Drying Technology, 2018
Anna Shershneva, Anastasiya Murueva, Elena Nikolaeva, Ekaterina Shishatskaya, Tatiana Volova
Biopharmacology perceives the development of the antitumor drug as one of the top priority research. The drugs such as taxane derivatives and pyrimidine antagonists are well documented against different types of cancer such as lung cancer, ovarian cancer, prostate cancer, etc. The ongoing efforts to evaluate antitumor drugs are often bound with myriad limitations such as low selectivity and high systemic toxicity which leads to the adverse effects on the individual health. The situation becomes deleterious with immunocompromised patients. In most cases, the efficacy and dosage of anticancer drugs do not exhibit the complete activity. In the current scenario, minimizing the toxicity of chemotherapy and enhancing the drug solubility with a specific mode of action on tumor cells have become subjects of interest for various scientific studies. Based on these facts, different strategies are implemented to enhance the therapeutic index of the drug for instance, encapsulation of antitumor drugs. One such method includes the development of new dosage of chemotherapeutic agents in the form of nano/microparticles from biodegradable and biocompatible polymers.[123] There are different polymers which are widely in practice, but they usher their own toxicity and few are reported to cause severe allergic reactions. Hence, care must be taken during the selection of polymers to develop nano/microparticles.